- About
- Projects
- Column 1
- Animal Health & Veterinary Medicine
- Expanded Access
- FDA Patient Listening Sessions
- Food & Nutrition
- Column 2
- Column 1
- News and Events
- Expanded Access eRequest
A cornucopia of new bills; Canadians support end-of-life psilocybin therapy; and tempering the hype - The Microdose
The Reagan-Udall Foundation, a non-profit created to advance the work of the U.S. Food and Drug Administration, held a two-day conference this week on current psychedelic research and clinical study design.
FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000 - Benzinga
The U.S. Food and Drug Administration (FDA) together with the Reagan-Udall Foundation for the FDA are hosting a virtual public meeting on psychedelic research, Jan. 31 to Feb. 1.
Titled "Advancing Psychedelic Clinical Study Design," the event aims to explore "empiric approaches to address key issues in psychedelic drug development and research."